Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Editas Medicine (EDIT) has 7 years of Operating Leases data on file, last reported at $12.1 million in Q4 2025.

• Operating Leases for Q4 2025 came in at $12.1 million, down 40.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.1 million (down 40.77% YoY), and the FY2025 annual result was $12.1 million, down 40.77% from the prior year.
• Operating Leases slipped to $12.1 million in Q4 2025 per EDIT's latest filing, from $13.6 million in the prior quarter.
• Over five years, Operating Leases peaked at $32.9 million in Q4 2022 and troughed at $9.3 million in Q3 2022.
• A 5-year average of $19.5 million and a median of $20.4 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases tumbled 52.5% in 2022, then surged 167.13% in 2023.
• A 5-year view of Operating Leases shows it stood at $16.1 million in 2021, then soared by 104.52% to $32.9 million in 2022, then declined by 25.84% to $24.4 million in 2023, then slipped by 16.38% to $20.4 million in 2024, then slumped by 40.77% to $12.1 million in 2025.
• Business Quant data shows EDIT's Operating Leases at $12.1 million in Q4 2025, $13.6 million in Q3 2025, and $15.0 million in Q2 2025.